What's new

Orphan designation: Entospletinib Treatment of acute myeloid leukaemia, 16/10/2017 Withdrawn

Orphan designation: Entospletinib Treatment of acute myeloid leukaemia, 16/10/2017 Withdrawn

Jun 10, 2025 - 08:25
 0
Orphan designation: Entospletinib Treatment of acute myeloid leukaemia, 16/10/2017 Withdrawn
Orphan designation: Entospletinib Treatment of acute myeloid leukaemia, 16/10/2017 Withdrawn
Read More

Tags:

Previous Article

Orphan designation: human IgG1 monoclonal antibody against sortilin Treatment of...

Next Article

Orphan designation: 1-(4-(6-chloropyridazin-3-yl)piperazin-1-yl)-2-(4-cyclopropy...

Related Posts

Human medicines European public assessment report (EPAR): Riximyo, rituximab, Date of authorisation: 15/06/2017, Revision: 16, Status: Authorised

Human medicines European public assessment report (EPAR...

May 28, 2025  0

PSUSA/00001842/202410

PSUSA/00001842/202410

Jun 6, 2025  0

Human medicines European public assessment report (EPAR): Imcivree, setmelanotide, Date of authorisation: 16/07/2021, Revision: 12, Status: Authorised

Human medicines European public assessment report (EPAR...

Jun 3, 2025  0